Article
Polymer Science
Airi Harui, Michael D. Roth
Summary: In this study, peri-tumor administration of hydrogel-encapsulated anti-CTLA-4 was found to specifically target tumor-draining lymph nodes, and the inclusion of hyaluronidase enhanced this targeting effect. These findings provide a theoretical basis for further optimizing immunotherapy.
Article
Oncology
Yosuke Sato, Cierra N. Casson, Atsushi Matsuda, James Kim, Judy Qiuju Shi, Shinji Iwasaki, Susan Chen, Brett Modrell, Chingkit Chan, Daniel Tavares, Douglas Austen, Koh Ida, Olga Tayber, Pyae Hein, Robert Comeau, Yafang Lin, Michael H. Shaw
Summary: Fc-independent functions of anti-CTLA-4 antibodies play a significant role in inhibiting tumor growth.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Zena N. Willsmore, Ben G. T. Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J. Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M. Hoffmann, Mano Nakamura, Roman Laddach, Jenny L. C. Geh, Alastair MacKenzie-Ross, Ciaran Healy, Sophia Tsoka, James F. Spicer, Debra H. Josephs, Sophie Papa, Katie E. Lacy, Sophia N. Karagiannis
Summary: CTLA-4 and PD-1 are immune checkpoint molecules that are targets of antibody immunotherapies for malignant melanoma. Combination therapy with immune checkpoint inhibitors may have better outcomes compared to monotherapy in certain patient groups, but also presents challenges and increased rates of adverse events.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Katie M. Campbell, Meelad Amouzgar, Shannon M. Pfeiffer, Timothy R. Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S. Weber, Jedd D. Wolchok, James Larkin, F. Stephen Hodi, Silvia Boffo, Lisa Salvador, Daniel Tenney, Tracy Tang, Marshall A. Thompson, Christine N. Spencer, Daniel K. Wells, Antoni Ribas
Summary: Immune checkpoint inhibitors (ICIs) such as CTLA-4 and PD-1-blocking antibodies have significant effects on tumor immune cell infiltration. In this study, we analyzed molecular datasets from 514 patients with advanced melanoma to explore the features of anti-PD-1 response. We found that prior anti-CTLA-4 therapy is associated with genomic and transcriptomic differences in anti-PD-1 responders, suggesting that the tumor microenvironment plays a role in predicting the response to PD-1 blockade therapy.
Article
Oncology
Simon Fietz, Romina Zarbl, Dennis Niebel, Christian Posch, Peter Brossart, Gerrit H. Gielen, Sebastian Strieth, Torsten Pietsch, Glen Kristiansen, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich
Summary: CTLA4 methylation is a predictive biomarker for response to anti-CTLA-4 immunotherapy, significantly associated with progressive tumors and progression-free survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Brianna M. Lax, Joseph R. Palmeri, Emi A. Lutz, Allison Sheen, Jordan A. Stinson, Lauren Duhamel, Luciano Santollani, Alan Kennedy, Adrienne M. Rothschilds, Stefani Spranger, David M. Sansom, K. Dane Wittrup
Summary: Anti-CTLA-4 antibodies have limited long-term benefit in tumor regression. We engineered a nonantagonistic CTLA-4 binding domain and found that both CTLA-4 antagonism and intratumoral Treg depletion are needed for maximum efficacy in anti-CTLA-4 therapy.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Immunology
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L. Cleary, Mimoza Boden, Linda Martensson, Johann Foloppe, Ingrid Teige, Eric Quemeneur, Bjorn Frendeus
Summary: This study demonstrates a highly effective and safe strategy to target CTLA-4 using a vectorized alpha CTLA-4 with strong Treg-depleting and checkpoint-blocking properties. This approach shows promising results in enhancing anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Plant Sciences
Christine Joy I. Bulaon, Narach Khorattanakulchai, Kaewta Rattanapisit, Hongyan Sun, Nuttapat Pisuttinusart, Richard Strasser, Shiho Tanaka, Patrick Soon-Shiong, Waranyoo Phoolcharoen
Summary: This study demonstrates the production of anti-CTLA-4 2C8 antibody using Nicotiana benthamiana as a plant expression system and validates its efficacy in inhibiting tumor growth through animal experiments. It highlights the potential of plant platforms in cancer immunotherapy.
FRONTIERS IN PLANT SCIENCE
(2023)
Article
Oncology
Yoshiyasu Umeda, Shusuke Yoshikawa, Yukiko Kiniwa, Takeo Maekawa, Osamu Yamasaki, Taiki Isei, Shigeto Matsushita, Motoo Nomura, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Tatsuya Takenouchi, Ryo Tanaka, Hiroshi Kato, Atsushi Otsuka, Taisuke Matsuya, Natsuki Baba, Kotaro Nagase, Takashi Inozume, Takehiro Onuma, Yutaka Kuwatsuka, Noriki Fujimoto, Takahide Kaneko, Masazumi Onishi, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Nakamura
Summary: The study found that the combination of radiotherapy (RT) with immune checkpoint inhibitors (ICIs) did not result in a significant survival benefit for patients with mucosal melanoma (MUM), although it may help improve local tumor control and relieve local symptoms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Craig L. Slingluff, Hassane M. Zarour, Hussein Abdul-Hassan Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander, Craig E. Devoe, Elizabeth M. Gaughan, Ileana S. Mauldin, Walter C. Olson, Kelly T. Smith, Mary J. Macri, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok
Summary: Treatment with IPI + NY-ESO-1 vaccines enhanced T cell and antibody responses in patients. Patients with best clinical responses had broader antibody responses and increased T cell densities.
Article
Oncology
Y. Nakamura, K. Namikawa, S. Yoshikawa, Y. Kiniwa, T. Maekawa, O. Yamasaki, T. Isei, S. Matsushita, M. Nomura, Y. Nakai, S. Fukushima, S. Saito, T. Takenouchi, R. Tanaka, H. Kato, A. Otsuka, T. Matsuya, N. Baba, K. Nagase, T. Inozume, N. Fujimoto, Y. Kuwatsuka, M. Onishi, T. Kaneko, T. Onuma, Y. Umeda, D. Ogata, A. Takahashi, M. Otsuka, Y. Teramoto, N. Yamazaki
Summary: In a study of advanced mucosal melanoma patients in Japan, it was found that there was no significant difference in efficacy between PD1 and PD1 + CTLA4, but the latter had a higher incidence of immune-related adverse events.
Article
Oncology
Prachi Bhave, Tasnia Ahmed, Serigne N. Lo, Alexander Shoushtari, Anne Zaremba, Judith M. Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K. Schwarze, Meghan J. Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U. Blank, Egle Ramelyte, Katharina C. Kaehler, Severine Roy, Paolo A. Ascierto, Olivier Michielin, Paul C. Lorigan, Douglas B. Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A. McArthur, Andrew M. Haydon, Georgina Long, Alexander M. Menzies, Matteo S. Carlino
Summary: Acral melanoma is a rare subtype with poor prognosis, and there is a lack of prospective clinical trial evidence on the efficacy of checkpoint inhibitors in this population. The study found that initial anti-PD-1/ipilimumab combination had a significantly higher ORR compared to anti-PD-1 alone, but this benefit did not translate to improved OS in this retrospective cohort. Primary site did not impact treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Doreen Lau, Mary A. McLean, Andrew N. Priest, Andrew B. Gill, Francis Scott, Ilse Patterson, Bruno Carmo, Frank Riemer, Joshua D. Kaggie, Amy Frary, Doreen Milne, Catherine Booth, Arthur Lewis, Michal Sulikowski, Lee Brown, Jean-Martin Lapointe, Luigi Aloj, Martin J. Graves, Kevin M. Brindle, Pippa G. Corrie, Ferdia A. Gallagher
Summary: Multiparametric MRI showed potential for early detection of successful response to immune checkpoint inhibitors in metastatic melanoma. Significant intertumoral heterogeneity in tumor growth kinetics and early detection of tumor cell death or loss were observed. Tumor heterogeneity measured by apparent diffusional kurtosis was consistently higher in non-responding lesions compared to responding lesions throughout the first 12 weeks of treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tuba N. Gide, Ines Pires da Silva, Camelia Quek, Peter M. Ferguson, Marcel Batten, Ping Shang, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P. M. Saw, John F. Thompson, Richard A. Scolyer, Georgina V. Long, James S. Wilmott
Summary: While immune checkpoint inhibitors targeting CTLA-4 and PD-1 have improved outcomes for many patients with metastatic melanoma, there remains a subset of patients who do not respond. This study identified two distinct groups of non-responders based on their gene expression profiles, highlighting the importance of a personalized approach for identifying effective treatments for anti-PD-1 resistant patients.
